Abstract
EP12.01-10 Predictors of Poor Outcomes Among Patients Receiving 1st-Line Osimertinib for Advanced EGFR Mutated Non-Small Cell Lung Cancer
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have